10.3 Capital Budgeting

Capital Budgeting

Quick Answer: Capital budgeting is the process of evaluating, prioritizing, funding, and controlling long-lived investments—facilities, equipment, IT, and strategic ventures. Executives must weigh funding sources, long-term financial and operational implications, depreciation, and value analysis (clinical and financial), not only purchase price. On the FACHE exam (Finance F3), capital decisions are judged by multi-year impact on cash, debt capacity, mission, and risk.

A $40 million OR renovation or $120 million EHR program can shape cost structure and competitive position for a decade. Fellows must run capital as a portfolio under governance—not a political queue of departmental wish lists.

What Counts as Capital

Capital expenditures typically involve assets with useful lives beyond one year and material cost thresholds defined by policy (e.g., equipment over $5,000). Categories include:

• Facilities and infrastructure: towers, ambulatory buildings, HVAC, infrastructure
• Clinical equipment: imaging, robotics, monitors, lab analyzers
• Information technology: EHR, ERP, cybersecurity, telehealth platforms
• Strategic capital: acquisitions, joint ventures, ambulatory network builds
• Routine replacement: beds, sterilizers, fleet—often under-prioritized until failure

Capital vs. operating expense: software subscriptions and some cloud services may be operating (OpEx) under current accounting, even when strategically "big." Executives analyze total cost of ownership (TCO) and cash timing regardless of book classification.

The Capital Budgeting Process

1. Strategy alignment — Does the request advance approved strategic priorities (access, quality, growth, risk reduction)?
2. Demand and clinical need — Volume forecasts, condition of existing assets, regulatory/safety requirements, physician alignment.
3. Options analysis — Replace, renovate, lease, outsource, do nothing, or phased approach.
4. Financial evaluation — Cash flows, NPV/IRR/payback where quantifiable; cost of capital; sensitivity.
5. Nonfinancial evaluation — Safety, quality, equity of access, workforce, community benefit, competitive necessity.
6. Prioritization and portfolio balance — Scorecards, mandatory vs. discretionary, risk, and timing.
7. Funding decision — Cash, debt, philanthropy, leases, grants, partnerships.
8. Board/governance approval — Thresholds for management vs. board authorization.
9. Implementation control — Project managers, change orders, contingency, benefits realization.
10. Post-completion review — Did volume, cost, and quality benefits materialize?

Funding Sources and Their Implications

Scenario — Ambulatory surgery center. A system can build with cash (DCOH falls from 180 to 140 days), issue bonds (preserves cash but raises debt-to-capitalization and DSCR scrutiny), partner with surgeons (aligns volume but shares margin and control), or lease shell space (faster, less ownership of residual asset). The "cheapest sticker price" is rarely the full decision.

Financial Evaluation Tools

• Payback period: years to recover investment from cash inflows—simple, ignores time value and post-payback cash.
• Net present value (NPV): present value of cash inflows minus outflows discounted at cost of capital—positive NPV adds economic value under the assumptions.
• Internal rate of return (IRR): discount rate that sets NPV to zero—compare to hurdle rate.
• Profitability index / benefit-cost: useful when capital is rationed.
• Sensitivity and scenario analysis: volume −10%, rate cuts, construction overrun, delayed go-live.
• Break-even volume: how many cases or visits to cover fixed capital-related costs.

Trap: Forcing every safety or compliance project to show positive NPV. Some capital is mandatory (fire code, life safety, cybersecurity, failed critical equipment). Portfolio management funds must-dos first, then ranks strategic and ROI projects.

Trap: Optimistic volume in physician-requested equipment without market analysis or medical staff development plans. Capital waste often starts as "the robot will pay for itself" without a realistic case schedule.

Depreciation: Book Reality and Decision Reality

Depreciation allocates the cost of a tangible long-lived asset over its useful life (straight-line is most common in healthcare management discussions; accelerated methods may appear for tax in for-profit settings).

Executive points:

• Depreciation is non-cash expense but signals capital consumption—assets wear out and must be replaced.
• Under-depreciating culture or deferred replacement creates hidden future capital cliffs.
• For DSCR and many coverage calculations, depreciation is added back to earnings because cash was not spent that period—yet free cash must still fund replacements.
• Accumulated depreciation and age of plant ratios help boards see how old the asset base is.
• New capital increases future depreciation, which pressures operating income even when cash debt service is separate—communicate both cash and accrual views to clinical leaders.

Scenario — Imaging replacement. A 12-year-old CT nears end of life. Book value is low; maintenance costs and downtime are high. Capital request looks expensive, but avoiding replacement risks quality, throughput, and emergency rental costs. Value analysis compares downtime, dose/quality, service contracts, and residual risk—not only NPV of fee-for-service scans in a shifting payment model.

Value Analysis in Capital Decisions

Value analysis (and related value analysis committees for supplies/devices) asks: what clinical and operational value do we get per dollar, with evidence?

For capital equipment and projects:

• Clinical outcomes and safety evidence
• Throughput and access (wait times, OR utilization)
• Staffing implications (does new tech need new competencies or reduce FTE need?)
• Lifecycle costs: maintenance, consumables, upgrades, cybersecurity, utilities, training
• Standardization vs. preference items (physician preference items drive cost variation)
• Equity: does the investment improve access for underserved sites or concentrate resources only at the flagship?
• Alternatives: refurbished equipment, mobile services, referral partnerships

Governance often uses a capital scoring model: strategic fit, financial return, risk/regulatory necessity, quality/safety, community need—weights set by leadership and board finance committee.

Long-Term Implications Executives Must Stress-Test

Capital decisions lock in:

• Debt service and covenants for years
• Operating costs (staffing a new wing, IT analysts, biomed, utilities)
• Strategic flexibility (or inflexibility if specialized plant cannot be repurposed)
• Competitive position (outpatient shift—investing only in inpatient towers can strand capital)
• Credit rating trajectory affecting future cost of capital
• Mission trade-offs (community benefit capacity if liquidity is drained)

Integration with operating budgets: every major capital approval should include a multi-year operating pro forma—not a one-page purchase order. IT projects especially fail when capital is approved but optimization staffing is not.

Portfolio Prioritization Under Capital Rationing

Few systems can fund all requests. Disciplined executives:

• Separate mandatory, replacement, and strategic/growth pools
• Require completed business cases with owners and KPIs
• Avoid "first to lobby" prioritization
• Revisit multi-year capital plans annually as rates, volumes, and strategy change
• Track benefits realization 12–24 months post go-live

Scenario — System capital committee. Requests total $180M; capacity is $95M cash + debt. Mandatory life safety and EHR security take $40M. Remaining $55M is scored: ambulatory access in a growing suburb scores high on strategy and NPV; a low-volume inpatient unit renovation scores low. Committee defers cosmetic inpatient work and funds ambulatory—aligned with outpatient shift and debt capacity.

Bottom Line for Section 10.3

Capital budgeting evaluates long-lived investments with strategy, risk, and multi-year cash impacts in view. Funding sources (cash, debt, philanthropy, leases, partnerships) each change liquidity, leverage, and control. Depreciation and age-of-plant thinking keep replacement real; value analysis balances clinical evidence and lifecycle cost with financial tools like NPV, IRR, and payback. Fellows govern capital as a portfolio that protects mission and credit strength—not a catalog of isolated purchases.